Table 2.
Gene name | T1 versus N | T2 versus N | N (PE versus media) | T1 (PE versus media) | T2 (PE versus media) |
---|---|---|---|---|---|
Apaf1 | 0.8 | 2.2 | 0.01 | 1.4 | 8.4 |
APRIL | 0.04 | 0.03 | 4.5 | 2.5 | 107.9 |
Bad | 0.1 | 0.2 | 0.0 | 1.7 | 5.4 |
Bax | Up | Up | 3.8 | 1.8 | 6.2 |
Bcl2 | 0.04 | 0.2 | 0.4 | 0.2 | 1.2 |
Bid | Down | Down | 3.2 | Up | Up |
Casp1 | 0.0 | 0.05 | 0.01 | 64.8 | 132.3 |
Casp3 | 0.4 | 247.5 | Up | 1.5 | Down |
Casp8 | 0.2 | 0.7 | 3.8 | 2.4 | 5.6 |
Casp9 | Down | Down | 3.4 | 1.5 | Up |
TRAIL-R/DR5 | Up | Up | 3.8 | 1.6 | 13.7 |
TRAIL | Down | 0.9 | 4.4 | 1.5 | 6.2 |
Tramp/Apo-3/DDR3 | 0.1 | 1.1 | 2.8 | 1.1 | 0.3 |
Tnfsf12 (Apo-3L) | 0.01 | Down | 0.04 | 0.5 | Up |
CD40 | 0.06 | Down | 11.4 | Down | Up |
Fas antigen | Down | 0.4 | Up | 1.5 | Up |
Fas ligand | 60 | 0.5 | 3.8 | Up | Up |
p53 | 0.4 | 0.7 | 1.1 | 1.0 | 8.1 |
All three fibroblast cell lines were also analyzed in the presence and absence of IL13-PE (PE versus media) treatment. Data shown indicate fold induction in gene expression compared with normal fibroblasts (column 1 and 2) or compared with untreated fibroblasts cell lines (columns 3 to 5).